Successful treatment by mycophenolate mofetil of subacute progressive interstitial lung disease associated with systemic lupus erythematosus

Abstract

Symptomatic interstitial lung disease (ILD) is rare in systemic lupus erythematosus (SLE), and there is no established treatment for it. We report a case of subacute progressive ILD in a patient with SLE, which was successfully treated by mycophenolate mofetil. Mycophenolate mofetil may be a promising therapeutic choice for SLE-associated ILD.

Keywords:

• Systemic lupus erythematosus
• interstitial lung disease
• mycophenolate mofetil
• subacute
• steroid

Patient consent

The patient signed an informed consent to publish this report.

Ethical statement

An Ethical Approval Statement was not required for this manuscript.

Conflict of interest

K. Fujio has received grants, consulting fees, speaking fees, and/or honoraria from Mitsubishi Tanabe, BMS, Eli Lilly, Chugai, Janssen, Pfizer, Ono, AbbVie, Ayumi, Astellas, Sanofi, Novartis, Daiichi-Sankyo, Eisai, Asahi Kasei, MSD, and the Japan Blood Products Organisation. All the other authors declared no conflicts of interest.

Additional information

Funding

This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sectors.